Arecor Therapeutics plc

LSE AREC.L

Arecor Therapeutics plc Price to Book Ratio (P/B) on January 24, 2025: 2.27

Arecor Therapeutics plc Price to Book Ratio (P/B) is 2.27 on January 24, 2025, a -66.25% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Arecor Therapeutics plc 52-week high Price to Book Ratio (P/B) is 6.59 on February 01, 2024, which is 189.73% above the current Price to Book Ratio (P/B).
  • Arecor Therapeutics plc 52-week low Price to Book Ratio (P/B) is 2.16 on December 20, 2024, which is -4.80% below the current Price to Book Ratio (P/B).
  • Arecor Therapeutics plc average Price to Book Ratio (P/B) for the last 52 weeks is 4.22.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
SV Wall Street
LSE: AREC.L

Arecor Therapeutics plc

CEO Dr. Sarah Jennifer Howell Ph.D.
IPO Date June 3, 2021
Location United Kingdom
Headquarters Chesterford Research Park
Employees 50
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Similar companies

POLB.L

Poolbeg Pharma PLC

USD 0.07

-3.12%

StockViz Staff

January 30, 2025

Any question? Send us an email